Targeted Chemotherapy Delivery Platform
Alpha Cancer Technologies Inc. (ACT) is advancing its targeted chemotherapy delivery platform based on Alpha FetoProtein (AFP) to enhance the performance of chemotherapy at lower dose with better safety.
AFP combined with chemotherapy targets cancer cells with a very high degree of selectivity. It has been shown to overcome drug resistance that many cancers develop in response to chemotherapy. This approach is highly selective for cancer cells that have AFP receptors (ovarian, lung, colon, gastric, liver, pancreatic cancers, leukemia, breast and more) and not cause damage to normal cells thus reducing systemic toxicity.
- 2014-05-28 - PolyTherics and Alpha Cancer Technologies Collaborate to Produce Novel Drug Conjugates to Target Tumours
- 2014-03-07 - Bradmer Announces Fourth Quarter and 2013 Operational and Financial Results
- 2014-02-19 - Bradmer Pharmaceuticals Inc. announces proposed reverse take-over transaction with Alpha Cancer Technologies Inc.